02/25/2026
A new study from the Balazs Lab at the Ragon Institute, published in Immunity, demonstrates that HIV escapes broadly neutralizing antibodies (bNAbs) through a limited set of conserved mutation paths, and that manipulating the cost of those paths can dramatically improve therapeutic outcomes.
"By studying the mutations the virus makes during selection by these antibodies, we find that the ease or difficulty of escape paths available to the virus are the real drivers of success or failure during treatment,” said principal investigator and corresponding author Alejandro Balazs, PhD.
“We believe this insight will be crucial for the development of future HIV therapies that employ combinations of antibodies that can exert orthogonal selective pressure on the virus to produce the check-mate conditions needed to continuously suppress HIV as a functional cure".
Read More: https://ragoninstitute.org/2026/02/balazs-lab-study-reveals-hiv-escapes-antibody-therapy-through-predictable-paths-and-blocking-them-can-achieve-sustained-viral-suppression/